Medications

Subcutaneous mAb may benefit high-risk outpatients with COVID-19

For high-risk outpatients with mild-to-moderate COVID-19, subcutaneously administered monoclonal antibody (mAb) treatment with casirivimab and imdevimab is associated with reduced risk for 28-day hospitalization or death ...

Medical research

Ivermectin does not prevent progression to severe COVID-19

Ivermectin treatment during early illness does not prevent progression to severe disease for high-risk patients with mild-to-moderate COVID-19, according to a study published online Feb. 18 in JAMA Internal Medicine.

Diseases, Conditions, Syndromes

Unvaccinated have highest SARS-CoV-2 incidence, hospitalization

(HealthDay)—Severe acute respiratory syndrome coronavirus 2 incidence and hospitalization rates are consistently higher for unvaccinated persons, and rates are lowest for those fully vaccinated with a booster, according ...

Diseases, Conditions, Syndromes

England sees no need for further restrictions—for now

U.K. Prime Minister Boris Johnson said Tuesday he hoped to "ride out" the pandemic without further restrictions, even as he warned that the country faces difficult days ahead as the highly transmissible omicron variant drives ...

page 8 from 34